Výsledky vyhledávání

Sustained Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B after Adefovir Dipivoxil Treatment: Analysis of Precore and Basal Core Promoter Mutants

Autor: Elsa Mondou, Ting-Tsung Chang, David Frederick, Mitchell L. Shiffman, Andrea Snow–Lampart, Franck Rousseau, I-Chin Wu, Patrick Marcellin, Jeff Sorbel, Myron J. Tong

Publikováno v: Clinical Infectious Diseases. 47:1305-1311

BACKGROUND This study evaluated the persistence of hepatitis B e antigen (HBeAg) seroconversion (which is considered to be an important therapeutic end point) after adefovir dipivoxil treatment. METHODS Forty-five patients who experienced confirmed H

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c624243b51b067626fde80ebddeb149
https://doi.org/10.1086/592570

Zobrazit plný text záznamu

Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B

Autor: Christian Trepo, M. R. Blum, Herve Mommeja-Marin, Cary Moxham, Seng Gee Lim, Patrick Marcellin, F. Rousseau, Andrea Snow, Hie-Won Hann, Nancy Leung, George K. K. Lau, Jeff Sorbel

Publikováno v: Alimentary Pharmacology & Therapeutics. 27:1282-1292

Summary Background Clevudine is a polymerase inhibitor that has the unusual feature of delayed viral rebound after therapy in some patients which may be related to its pharmacokinetics. Aim To characterize pharmacokinetic and pharmacodynamic profile

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5227093dbc62548f4ea2e135c10215f7
https://doi.org/10.1111/j.1365-2036.2008.03686.x

Zobrazit plný text záznamu

Plný text ve formátu HTML

Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B

Autor: Elsa Mondou, David Frederick, Franck Rousseau, J. Mizerski, Jeff Sorbel, Maureen M. Jonas, Henry Pollack, Deirdre Kelly, Etienne Sokal

Publikováno v: Hepatology. 47:1863-1871

This study investigated the efficacy, safety, and pharmacokinetics of adefovir dipivoxil (ADV) in children and adolescents with chronic hepatitis B (CHB). A total of 173 treatment-naive and treatment-experienced children with hepatitis B e antigen (H

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3be1647453f1d986f8ed49ae5d1ad86a
https://doi.org/10.1002/hep.22250

Zobrazit plný text záznamu

Impact of Early Viral Kinetics on T-Cell Reactivity during Antiviral Therapy in Chronic Hepatitis B

Autor: Franck Rousseau, Emi Shudo, Ruy M. Ribeiro, H. Cooksley, Jane Anderson, Sharon R Lewin, Chee Kin Hui, George K. K. Lau, Elsa Mondou, Stephen Locarnini, Alan S. Perelson, Kimberly A. Powers, Jeff Sorbel, Scott Bowden, Nikolai V. Naoumov

Publikováno v: Scopus-Elsevier
Europe PubMed Central

BackgroundThe patterns of hepatitis B viral dynamics during different antiviral therapies and the associated changes in HBV-specific T-cell reactivity are not well defined.MethodsWe investigated the impact of early viral load decline on virus-specifi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c19756c6a5e755b7d588ddf170017037
https://doi.org/10.1177/135965350701200513

Zobrazit plný text záznamu

Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: A two-year study

Autor: Michael W. Fried, Andrea Snow, Chia Wang, Franck Rousseau, Elsa Mondou, Robert G. Gish, Lawrence Corey, Francis K.L. Chan, J. Anderson, Huy N. Trinh, Teresa L. Wright, Nancy Leung, Jeff Sorbel

Publikováno v: Journal of Hepatology. 43:60-66

Background/Aims The aim of this study was to evaluate long term safety and antiviral activity of different doses of emtricitabine given once daily to patients chronically infected with hepatitis B. Methods Eligible patients were randomized in a doubl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83b35b1157ef5a508916c71aaa5b9dc3
https://doi.org/10.1016/j.jhep.2005.02.017

Zobrazit plný text záznamu

Posttreatment Exacerbation of Hepatitis B Virus (HBV) Infection in Long-Term HBV Trials of Emtricitabine

Autor: Jeff Sorbel, Elsa Mondou, H. Mommeja Marin, J. Anderson, F. Rousseau, A. Rigney

Publikováno v: Clinical Infectious Diseases. 41:e45-e47

Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine occurred in 23% of patients. Development of antibody to hepatitis e antigen did not prevent hepatic flare. One patient with marked bridging fibro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fb3b00a36d197c4a85d881d0d059b76
https://doi.org/10.1086/432581

Zobrazit plný text záznamu

Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection

Autor: Franck Rousseau, Elsa Mondou, Jeff Sorbel, Maureen M. Jonas, Henry Pollack, J. Mizerski, Etienne Sokal, Deirdre Kelly, David W. Frederick

Publikováno v: The Pediatric infectious disease journal. 31(6)

The safety and efficacy of adefovir dipivoxil (ADV) for chronic hepatitis B infection in children was demonstrated in a randomized, placebo-controlled trial. Those children were followed for 4 more years, and many continued to receive ADV for all or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24d498fb98bedf7134d8b3fae94f8497
https://pubmed.ncbi.nlm.nih.gov/22466329

Zobrazit plný text záznamu

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B

Publikováno v: Gastroenterology, 140(1), 132-143. W.B. Saunders

BACKGROUND & AIMS: Tenofovir disoproxil fumarate (TDF), a nucleotide analogue and potent inhibitor of hepatitis B virus (HBV) polymerase, showed superior efficacy to adefovir dipivoxil in treatment of chronic hepatitis B through 48 weeks. We evaluate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f691ef6c98e8b34052573db76babbb65
http://hdl.handle.net/11452/28987

Zobrazit plný text záznamu

No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus

Autor: James Schawalder, Brandi J. Chappell, Jeff Sorbel, Jenny Heathcote, Yuao Zhu, Maria Curtis, Evguenia S. Svarovskaia, Michael D. Miller, Patrick Marcellin, Kathryn M. Kitrinos, Katyna Borroto-Esoda, Andrea Snow-Lampart, Florence Myrick

Publikováno v: Hepatology (Baltimore, Md.). 53(3)

Tenofovir disoproxil fumarate (TDF) is a nucleotide analogue with potent activity against human immunodeficiency virus type 1 and hepatitis B virus (HBV). To date, no reports of HBV clinical resistance to TDF have been confirmed. In two phase 3 studi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df12ed118eef95a55107a5a3bd339600
https://pubmed.ncbi.nlm.nih.gov/21374657

Zobrazit plný text záznamu

Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection

Autor: Fabien Zoulim, E. Suárez, Fabien Lavocat, Bernd Möller, Jeff Sorbel, Katyna Borroto–Esoda, Huy N. Trinh, Sing Chan, David Oldach, David Frederick, Thomas Berg, Patrick Marcellin, Andrea Snow–Lampart, Franck Rousseau

Publikováno v: Gastroenterology. 139(4)

Background & Aims We compared treatments for patients with chronic hepatitis B virus (HBV) infection who had an incomplete response to adefovir dipivoxil (ADV). We evaluated a combination of fixed-dose emtricitabine (FTC) and tenofovir disoproxil fum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e279d0380882b49871e6c2d50b53dcda
https://pubmed.ncbi.nlm.nih.gov/20600025

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání